[4, 6, 25, 49, 50] While many of the reasons for treatment ineligibility were specific to PEG-IFN + RBV, this issue in linkage-to-care is multifactorial and related in part to the asymptomatic nature of CHC but also to a lack of the ability to provide extensive pre-treatment workup including serologic testing and assessment for liver fibrosis and inflammation.[6, 45, 49–51]. Here, IFNA1 is linked to cryohydrocytosis.